By Topic

Design and testing of acoustically-active therapeutic nanocapsule delivery vehicles for ultrasound-targeted chemotherapy

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$31 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

6 Author(s)
Mullin, L. ; Joint Dept. of Biomed. Eng., Univ. of North Carolina, Chapel Hill, NC, USA ; Ping Ma ; Wadhwa, S. ; Lei Peng
more authors

We propose that by utilizing acoustically-active delivery vehicles (AADVs), which combine the acoustic activity of an ultrasound contrast agent (UCA) with the high payload and extravasation ability of nanoparticles, we can overcome limitations of current chemotherapy delivery methodologies. AADV were formed by conjugating nanocapsules to the shell of biotinylated UCAs. Ultrasound parameters were optimized with a 2.25 MHz focused transducer using a flow phantom to achieve both acoustic radiation force and microbubble destruction. R3230 cells cultured on a cover slip were exposed to the AADV and sonicated with the focused transducer. Fluorescence microscopy verified binding of nanocapsules to ultrasound contrast agents to form AADVs, and increased delivery of nanocapsules to cells within the focus of the transducer (relative to nanocapsule delivery without ultrasound). An order-of magnitude increase in particles were delivered to cells exposed to ultrasound compared to unexposed cells.

Published in:

Ultrasonics Symposium (IUS), 2010 IEEE

Date of Conference:

11-14 Oct. 2010